Company intelligence / Profile preview
Cyxone
Malmö, Skåne County, Swedencyxone.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 2
01
Overview
Cyxone developed two main clinical-stage drug candidates targeting autoimmune diseases. Rabeximod reached phase II trials in rheumatoid arthritis, while T20K completed phase I studies in multiple sclerosis. Both programs aimed to offer safer, more effective oral therapies compared to existing treatments. The company’s patent position was strengthened through collaboration with the Medical University of Vienna regarding T20K technology. As of late 2024, the company appears inactive on public markets.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small moleculeCyclotide-based drugPeptide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Medical University of Vienna
Beyond the preview
Go deeper on Cyxone.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyxone.